UACC-893細(xì)胞

運(yùn)輸方式： 凍存運(yùn)輸

ATCC Number： CRL-1902?

相關(guān)**： 導(dǎo)管癌

年限： 57 years

細(xì)胞形態(tài)： 上皮樣

是否是腫瘤細(xì)胞： 1

物種來源： 人

生長(zhǎng)狀態(tài)： 貼壁生長(zhǎng)

器官來源： **

數(shù)量： 大量

Designations: UACC-893

UACC-893細(xì)胞Depositors: A Liebovitz, J Trent

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: mammary gland; breast

Disease: primary ductal carcinoma

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The breast carcinoma UACC-893 was deposited in the ATCC by Albert Leibovitz and Jeffrey M. Trent, Arizona Cancer Center, University of Arizona, Tucson, Arizona.These cells are distributed for research purposes only. The University of Arizona releases the line subject to the following: 1.UACC-893細(xì)胞UACC-893 cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of the University of Arizona; 2. Any proposed commercial use of these cells must first be negotiated with The Director of The Arizona Cancer Center, University of Arizona, 1501 N. Campbell Ave., Tucson, AZ 85724. Telephone (602) 626-7925, FAX (602) 626-2284; 3. In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publications (Proc. Am. Assoc. Cancer Res. 29: 24, 1988; Br. J. Cancer 63: 727-735, 1991).

DNA Profile (STR): Amelogenin: X

CSF1PO: 11,12

D13S317: 13

D16S539: 9,13

D5S818: 12

D7S820: 11

THO1: 6,9.3

TPOX: 8

vWA: 16,17

Cytogenetic Analysis: modal number = 62; range = 51 to 65

Age: 57 years

Gender: female

Ethnicity: Caucasian

Comments: UACC-893細(xì)胞This cell line was established by A. Liebovitz and associates in 1987 from breast tissue removed at lumpectomy to remove a ductal carcinoma (stage II). Prior to surgery, the patient had received no chemotherapy.The cells exhibit a 20 fold amplification of the HER-2/neu oncogene sequence. They are negative for estrogen receptors, progesterone receptors and P glycoprotein.The cells grow very slowly, and growth can be enhanced by using 20% fetal bovine serum and adding epidermal growth factor (10 ng/ml) to the medium.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Atmosphere: air, 100%

Temperature: 37.0°C

Subculturing: Protocol:

Remove and discard culture medium.

Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.

Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.

Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

Add appropriate aliquots of the cell suspension to new culture vessels.

Incubate cultures at 37?C.

Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended

Medium Renewal: Every 2 to 3 days

Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%

Storage temperature: liquid nitrogen vapor temperature

Doubling Time: 100 hrs

Related Products: UACC-893細(xì)胞Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2008

recommended serum:ATCC 30-2020

purified DNA:ATCC CRL-1902D

0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++):ATCC 30-2101

Cell culture tested DMSO:ATCC 4-X

References: 22207: . . Proc. Am. Assoc. Cancer Res. 29: 24, 1988.

26165: Meltzer P, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br. J. Cancer 63: 727-735, 1991. PubMed: 1674877